FGFR2 and intrahepatic cholangiocarcinoma: Antitumor activity is also observed for pemigatinib (8), a reversible, ATP competitive, pan-FGFR inhibitor, and futibatinib (9), an irreversible, pan-FGFR inhibitor in patients with FGFR2 fused and rearranged ICC.